The best indicator for Injective (INJ)
We backtested 20 indicators across daily, weekly and hourly charts on real Injective (INJ) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
ADX / DMI
On the daily chart, this is the strongest risk-adjusted edge we found for Injective (INJ) over ~8.2 years — beating buy-and-hold by 15.2% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Heikin-Ashi Trend | Weekly | 54.0% | 0.89 | -85.2% | 44.9% | 49 | 17.3% |
| 2 | ADX / DMI ✓ | Daily | 41.9% | 0.83 | -83.0% | 25.0% | 44 | 15.2% |
| 3 | EMA 20/50 Cross ✓ | Daily | 40.6% | 0.82 | -85.5% | 26.3% | 19 | 14.0% |
| 4 | RSI Trend (>50) | Daily | 34.2% | 0.76 | -92.8% | 36.8% | 106 | 7.6% |
| 5 | Donchian Breakout ✓ | Daily | 33.8% | 0.76 | -74.6% | 39.3% | 28 | 7.2% |
| 6 | Donchian Midline | Daily | 34.2% | 0.75 | -87.0% | 39.7% | 121 | 7.5% |
| 7 | Rate of Change | Daily | 30.7% | 0.72 | -88.6% | 37.1% | 124 | 4.1% |
| 8 | Bollinger Breakout ✓ | Daily | 24.5% | 0.65 | -80.5% | 34.1% | 41 | -2.1% |
| 9 | EMA-10 Trend | Weekly | 22.5% | 0.64 | -83.9% | 33.3% | 24 | -14.2% |
| 10 | Rate of Change | Weekly | 16.9% | 0.59 | -80.8% | 33.3% | 21 | -19.9% |
| 11 | EMA-10 Trend | Daily | 10.3% | 0.5 | -92.8% | 41.6% | 197 | -16.3% |
| 12 | RSI Trend (>50) | Weekly | 13.9% | 0.54 | -79.6% | 7.7% | 13 | -22.9% |
| 13 | MACD | Daily | 4.5% | 0.43 | -92.9% | 37.8% | 82 | -22.1% |
| 14 | Donchian Midline | Weekly | 18.2% | 0.58 | -66.9% | 27.3% | 11 | -18.6% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Injective (INJ), ADX / DMI on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More crypto
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.